Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biosubtyl DL
- Development stage
- Unknown
- Lead developer
- Institute of Vaccines and Medical Biologicals
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Biosubtyl DL is a probiotic and digestive enzyme supplement developed and manufactured by Dalat Pasteur Vaccines (DAVAC) in Vietnam. It is formulated as an oral powder containing two primary probiotic strains: *Bacillus subtilis* and *Lactobacillus acidophilus*. The product is indicated for the treatment of diarrhea, acute and chronic enteritis or colitis, and digestive disorders resulting from antibiotic use. Its mechanism of action involves modulating the gut microbiota to restore intestinal flora balance and supporting digestion through the production of enzymes such as protease and amylase. It is classified as an over-the-counter (OTC) medication in Vietnam.
- Brand names
- Biosubtyl DL
- Other names
- Biosubtyl-DL
02
Targets
AMY (Pancreatic alpha-amylase)
Beyond the preview
Go deeper on Biosubtyl DL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biosubtyl DL.